Axsome Therapeutics Announces First Patient Dosed In FOCUS-3 Phase 3 Trial Evaluating Solriamfetol As Treatment For Adolescents With Attention Deficit Hyperactivity Disorder

뉴스 본문을 불러오고 있어요.

Axsome Therapeutics Announces First Patient Dosed In FOCUS-3 Phase 3 Trial Evaluating Solriamfetol As Treatment For Adolescents With Attention Deficit Hyperactivity Disorder | 웨이프 WAPE

Axsome Therapeutics Announces First Patient Dosed In FOCUS-3 Phase 3 Trial Evaluating Solriamfetol As Treatment For Adolescents With Attention Deficit Hyperactivity Disorder

기사 요약

관련 종목

댓글 —